- Home
- PRME vs NNAVW Comparison
PRME vs NNAVW Comparison
Compare PRME & NNAVW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRME | NNAVW |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | United States | United States |
| Employees | N/A | 103 |
| Industry | Medicinal Chemicals and Botanical Products | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.4M | N/A |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRME | NNAVW |
|---|---|---|
| Price | $3.06 | $10.09 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $7.56 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 226.1K |
| Earning Date | 05-08-2026 | 03-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,632,000.00 | ★ $4,963,000.00 |
| Revenue This Year | $7.06 | N/A |
| Revenue Next Year | $47.01 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 55.28 | 43.44 |
| 52 Week Low | $1.40 | $3.90 |
| 52 Week High | $6.94 | $13.41 |
Technical Indicators
Market Signals| Indicator | PRME | NNAVW |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 50.32 |
| Support Level | $2.68 | $5.09 |
| Resistance Level | $3.72 | $12.99 |
| Average True Range (ATR) | 0.27 | 1.60 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 39.24 | 38.92 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
About NNAVW NextNav Inc. Warrant
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system delivers resilient, next-generation, complementary positioning, navigation, and timing (PNT) solutions designed to overcome the limitations and vulnerabilities of existing space-based Global Navigation Satellite Systems (GNSS), including the Global Positioning System (GPS). The products of the company include NextNav Pinnacle: Accurate vertical location, NextNav 3D: 3D location visualization, NextNav TerraPoiNT: Resilient PNT for 3D and indoor geolocation, Next Generation Solution: Terrestrial 3D PNT powered by spectrum.